Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC boosted its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 340.4% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 1,747,955 shares of the company’s stock after acquiring an additional 1,351,055 shares during the quarter. Renaissance Technologies LLC owned about 0.84% of Allogene Therapeutics worth $4,073,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ALLO. Bourgeon Capital Management LLC increased its stake in shares of Allogene Therapeutics by 12.8% in the 1st quarter. Bourgeon Capital Management LLC now owns 57,200 shares of the company’s stock valued at $256,000 after purchasing an additional 6,500 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in Allogene Therapeutics by 85.1% in the first quarter. CANADA LIFE ASSURANCE Co now owns 17,750 shares of the company’s stock valued at $79,000 after acquiring an additional 8,162 shares during the last quarter. Nisa Investment Advisors LLC raised its position in Allogene Therapeutics by 429.6% in the second quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company’s stock valued at $25,000 after purchasing an additional 8,734 shares during the period. Arizona State Retirement System raised its position in Allogene Therapeutics by 36.1% in the second quarter. Arizona State Retirement System now owns 40,915 shares of the company’s stock valued at $95,000 after purchasing an additional 10,855 shares during the period. Finally, Federated Hermes Inc. purchased a new stake in shares of Allogene Therapeutics during the second quarter worth $29,000. Institutional investors and hedge funds own 83.63% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ALLO. HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Allogene Therapeutics in a report on Thursday, August 15th. Oppenheimer began coverage on shares of Allogene Therapeutics in a research note on Thursday, August 8th. They set an “outperform” rating and a $11.00 target price for the company. Canaccord Genuity Group reduced their price objective on shares of Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. Citigroup increased their target price on shares of Allogene Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $14.00 target price (down from $17.00) on shares of Allogene Therapeutics in a report on Friday, August 9th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.96.

Allogene Therapeutics Price Performance

ALLO stock opened at $2.91 on Friday. Allogene Therapeutics, Inc. has a 52-week low of $2.01 and a 52-week high of $5.78. The company’s 50 day simple moving average is $2.67 and its 200-day simple moving average is $2.94. The firm has a market capitalization of $608.19 million, a P/E ratio of -1.63 and a beta of 0.83.

Allogene Therapeutics (NASDAQ:ALLO) last posted its earnings results on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. Allogene Therapeutics had a negative net margin of 223,139.98% and a negative return on equity of 50.24%. Sell-side analysts predict that Allogene Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).